ScienceMarch 3, 2026
Eledon Pharmaceuticals (ELDN): CD40L Pathway, Tegoprubart, Transplant & ALS Pipeline — February 2026
Eledon Pharmaceuticals (Nasdaq: ELDN) is a clinical-stage biotech targeting the CD40L pathway with tegoprubart, an IgG1 anti-CD40L antibody. Phase 2 BESTOW kidn
By ObjectWire Editorial
ScienceMarch 3, 2026
Life Biosciences FDA Clearance: ER-100 Epigenetic Reprogramming Trial for Glaucoma & NAION — January 2026
The FDA cleared Life Biosciences
By ObjectWire Editorial
ScienceFebruary 21, 2026
Bio-Hacking Hub: Human Enhancement, Longevity & Performance Optimization
Complete coverage of the bio-hacking movement — from Bryan Johnson
By ObjectWire Editorial
ScienceFebruary 21, 2026
Bianca Dias and the BBL Crisis: How
On February 19, 2026, in São Paulo, Brazil
By ObjectWire Editorial